【券商聚焦】中邮证券维持康臣药业(01681)“买入”评级称上半年集采以量换价取得成效下半年有望延续增长态势

金吾资讯08-23

金吾财讯 | 中邮证券发研报指，康臣药业(01681)：2024H1实现营收12.69亿元(+13.30%)；实现归母净利润4.00亿元(+14.91%)；毛利率74.69%，同比持平；费率管控较好，销售费用率32.47%(+0.14pct)，管理费用绝对值减少，促进管理费用率下降1.59pct至10.62%；归母净利率31.51%(+0.44pct)，盈利能力稳健向上。该行续指，2024上半年...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2461535061?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-23 13:43","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2461535061","market":"hk","top_or_hot":-1,"title":"【券商聚焦】中邮证券维持康臣药业(01681)“买入”评级 称上半年集采以量换价取得成效 下半年有望延续增长态势","media":"金吾资讯","content":"<div>\n<p>金吾财讯 | 中邮证券发研报指，康臣药业(01681)：2024H1实现营收12.69亿元(+13.30%)；实现归母净利润4.00亿元(+14.91%)；毛利率74.69%，同比持平；费率管控较好，销售费用率32.47%(+0.14pct)，管理费用绝对值减少，促进管理费用率下降1.59pct至10.62%；归母净利率31.51%(+0.44pct)，盈利能力稳健向上。该行续指，2024上半年...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082313434195b6c03e&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【券商聚焦】中邮证券维持康臣药业(01681)“买入”评级 称上半年集采以量换价取得成效 下半年有望延续增长态势</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【券商聚焦】中邮证券维持康臣药业(01681)“买入”评级 称上半年集采以量换价取得成效 下半年有望延续增长态势\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-23 13:43 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082313434195b6c03e&s=b><strong>金吾资讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>金吾财讯 | 中邮证券发研报指，康臣药业(01681)：2024H1实现营收12.69亿元(+13.30%)；实现归母净利润4.00亿元(+14.91%)；毛利率74.69%，同比持平；费率管控较好，销售费用率32.47%(+0.14pct)，管理费用绝对值减少，促进管理费用率下降1.59pct至10.62%；归母净利率31.51%(+0.44pct)，盈利能力稳健向上。该行续指，2024上半年...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082313434195b6c03e&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01681","symbol_name":"康臣药业","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082313434195b6c03e&s=b","article_id":"2461535061","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082313434195b6c03e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2461535061","pubTimestamp":1724391800,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"金吾财讯 | 中邮证券发研报指，康臣药业 ：2024H1实现营收12.69亿元；实现归母净利润4.00亿元；毛利率74.69%，同比持平；费率管控较好，销售费用率32.47%，管理费用绝对值减少，促进管理费用率下降1.59pct至10.62%；归母净利率31.51%，盈利能力稳健向上。该行续指，2024上半年公司采取了优化授权分管制度、加强临床学术研究力度、升级合规部门设置及改革OTC营销架构等重大举措，由此在集采扩面的形势下实现了以量换价。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"01681":"康臣药业"},"translate_title":"[Brokerage Focus] China Post Securities maintains the \"buy\" rating of Consun Pharmaceutical (01681), saying that centralized procurement in the first half of the year has achieved results in exchanging volume for price and is expected to continue the growth trend in the second half of the year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01681":1},"content_text":"金吾财讯 | 中邮证券发研报指，康臣药业(01681)：2024H1实现营收12.69亿元(+13.30%)；实现归母净利润4.00亿元(+14.91%)；毛利率74.69%，同比持平；费率管控较好，销售费用率32.47%(+0.14pct)，管理费用绝对值减少，促进管理费用率下降1.59pct至10.62%；归母净利率31.51%(+0.44pct)，盈利能力稳健向上。该行续指，2024上半年公司采取了优化授权分管制度、加强临床学术研究力度、升级合规部门设置及改革OTC营销架构等重大举措，由此在集采扩面的形势下实现了以量换价。下半年公司将进一步夯实发展基础、提升管理效率，明确战略规划和落地执行，优化预算考核机制，全面落实全年“稳增长，强合规，练内功”的工作方针，实现高质量可持续发展。该行预计2024-2026年公司收入分别为29.01/32.72/36.94亿元，归母净利润分别为8.93/10.22/11.70亿元，对应EPS分别为1.06/1.21/1.38元/股，当前最新收盘价对应PE分别为5.22/4.56/3.99倍，维持“买入”评级。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.0","shortVersion":"4.28.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2461535061"}

【券商聚焦】中邮证券维持康臣药业(01681)“买入”评级 称上半年集采以量换价取得成效 下半年有望延续增长态势

精彩评论

【券商聚焦】中邮证券维持康臣药业(01681)“买入”评级称上半年集采以量换价取得成效下半年有望延续增长态势